UK cancer monoclonal antibodies market is estimated to grow at a CAGR of 8.2% during the forecast period. The increasing prevalence of cancer and rising biomedical researches are some factors accelerating market growth. As per the World Health Organization (WHO), the number of new cancer incidences reported in the country was 446,942 in 2018. This includes prostate (12.6%), breast (12.4%), lung (11.7%), colorectum (10.7%), and others. These significant cancer incidences are leading to an increasing demand for targeted cancer therapies including monoclonal antibodies that serve as one of the potential alternatives to find and destroy cancer cells. 

Visit for Global Cancer Monoclonal Antibodies Market Report at: https://www.omrglobal.com/industry-reports/cancer-monoclonal-antibodies-market

It is one of the established therapeutic strategies for both solid tumors and hematologic malignancies. Some monoclonal antibody drugs that are available with their generic names in the UK include rituximab (Mabthera), trastuzumab (Herceptin), bevacizumab (Avastin), and pertuzumab (Perjeta). MabThera was the first monoclonal antibody therapeutics that aims to target cells containing CD20 marker on their surface. Such cells are central to several blood cancers, which include common types of leukaemia and lymphoma.

UK cancer monoclonal antibodies market is segmented based on type and application. Based on type, the market is classified into naked, conjugated, and others. Based on the application, the market is classified into breast cancer, liver cancer, blood cancer, brain cancer, colorectal cancer, and others. Naked monoclonal antibodies are the most common form of antibodies used for the treatment of cancer. Most naked monoclonal antibodies bind to antigens that are normally multiple on the surface of cancer cells compared to healthy cells. Bevacizumab (Avastin), Alemtuzumab (Lemtrada), Cetuximab (Erbitux), Trastuzumab (Herceptin), and Rituximab (Mabthera) are some naked monoclonal antibody drugs used for cancer treatment in the country. 

Some prominent players in the market include AstraZeneca plc, Pfizer Inc., Sitryx Therapeutics Ltd., Orchard Therapeutics plc, and Mylan N.V. Product launches and partnerships and collaborations are regarded as some potential strategies implemented by the market players to increase their position in the marketplace. For instance, in July 2020, AstraZeneca plc signed a global development and commercialization agreement with Daiichi Sankyo Company, Ltd. (Daiichi Sankyo) for DS-1062, a proprietary trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate of Daiichi Sankyo’s (ADC) and novel medicine to treat multiple tumor types. It is currently in development to treat multiple tumors that commonly sshow the cell-surface glycoprotein TROP2. 

Research Methodology

The market study of the UK cancer monoclonal antibodies market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity in our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. UK Cancer Monoclonal Antibodies Market Research and Analysis by Type
2. UK Cancer Monoclonal Antibodies Market Research and Analysis by Application

The Report Covers

• Comprehensive research methodology of the UK cancer monoclonal antibodies market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the UK cancer monoclonal antibodies market.
• Insights about market determinants which are stimulating the UK cancer monoclonal antibodies market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.